Express delivery and free returns within 21 days

Monday, June 27, 2022



Contact us 561.316.3330


Critical Care Immunotherapy

CytoSorbents Partners with InvoSurg and Surgical Partners

CytoSorbents is now aggressively expanding CytoSorb availability, marketing, and sales opportunities across the U.S. to help address the current and expected future waves of COVID-19 infection in the country.

CytoSorbents Awarded $4.4 Million Contract by the U.S. Department of Defense

CytoSorbents reports the HemoDefend-BGA filter is designed to enable "universal plasma", or plasma that can be administered to anyone regardless of blood type, and to improve the safety of whole blood transfusions, by the rapid and efficient removal of anti-A and anti-B antibodies from these two blood products.

CytoSorb, the Wuhan Coronavirus, and Cytokine Storm

In this publication, Huang, et al. describe the characteristics and clinical course of hospitalized patients infected with the Wuhan coronavirus who did, or did not, require treatment in the intensive care unit.

By using this website you agree to accept Medical Device News Magazine Privacy Policy